Accès gratuit
Editorial
Numéro
Méd. Intensive Réa.
Volume 28, Numéro 4, Juillet-Août 2019
Médecine interne et transversalité
Page(s) 287 - 289
Section Éditorial / Editorial
DOI https://doi.org/10.3166/rea-2019-0120
Publié en ligne 19 août 2019
  • Cairo MS, Bishop M, (2004) Tumour lysis syndrome: new therapeutic strategies and classification. Br J Haematol 127: 3–11 [CrossRef] [PubMed] [Google Scholar]
  • Soares M, Feres GA, Salluh JIF, (2009) Systemic inflammatory response syndrome and multiple organ dysfunction in patients with acute tumor lysis syndrome. Clinics 64: 479–481 [CrossRef] [PubMed] [Google Scholar]
  • Treuting PM, Albertson TM, Preston BD, (2010) Case series: acute tumor lysis syndrome in mutator mice with disseminated lymphoblastic lymphoma. Toxicol Pathol 38: 476–485 [CrossRef] [PubMed] [Google Scholar]
  • Jones GL, Will A, Jackson GH, Webb NJA, Rule S, the British Committee for Standards in Haematology, (2015) Guidelines for the management of tumour lysis syndrome in adults and children with haematological malignancies on behalf of the British Committee for Standards in Haematology. Br J Haematol 169: 661–671 [CrossRef] [PubMed] [Google Scholar]
  • Howard SC, Trifilio S, Gregory TK, Baxter N, McBride A, (2016) Tumor lysis syndrome in the era of novel and targeted agents in patients with hematologic malignancies: a systematic review. Ann Hematol 95: 563–573 [CrossRef] [PubMed] [Google Scholar]
  • Feng X, Dong K, Pham D, Pence S, Inciardi J, Bhutada NS, (2013) Efficacy and cost of single-dose rasburicase in prevention and treatment of adult tumour lysis syndrome: a meta-analysis. J Clin Pharm Ther 38: 301–308 [CrossRef] [PubMed] [Google Scholar]
  • Cortes J, Moore JO, Maziarz RT, Wetzler M, Craig M, Matous J, Wetzler M, Craig M, Matous J, Luger S, Dey BR, Schiller GJ, Pham D, Abboud CN, Krishnamurthy M, Brown A, Laadem A, Seiter K, (2010) Control of plasma uric acid in adults at risk for tumor lysis syndrome: efficacy and safety of rasburicase alone and rasburicase followed by allopurinol compared with allopurinol alone — results of a multicenter phase III study. J Clin Oncol 28: 4207–4213 [CrossRef] [PubMed] [Google Scholar]
  • Cheuk DKL, Chiang AKS, Chan GCF, Ha SY, (2014) Urate oxidase for the prevention and treatment of tumour lysis syndrome in children with cancer. Cochrane Database Syst Rev 8: CD006945 [Google Scholar]
  • Tamura K, Kawai Y, Kiguchi T, Okamoto M, Kaneko M, Maemondo M, Okamoto M, Kaneko M, Maemondo M, Gemba K, Fujimaki K, Kirito K, Goto T, Fujisaki T, Takeda K, Nakajima A, Ueda T, (2016) Efficacy and safety of febuxostat for prevention of tumor lysis syndrome in patients with malignant tumors receiving chemotherapy: a phase III, randomized, multi-center trial comparing febuxostat and allopurinol. Int J Clin Oncol 21: 996–1003 [CrossRef] [PubMed] [Google Scholar]
  • Agha-Razii M, Amyot SL, Pichette V, Cardinal J, Ouimet D, Leblanc M, (2000) Continuous veno-venous hemodiafiltration for the treatment of spontaneous tumor lysis syndrome complicated by acute renal failure and severe hyperuricemia. Clin Nephrol 54: 59–63 [PubMed] [Google Scholar]

Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.

Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.

Le chargement des statistiques peut être long.